FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119376616> ?p ?o ?g. }

• W3119376616 endingPage "811" @default.
• W3119376616 startingPage "800" @default.
• W3119376616 abstract "Introduction Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa monotherapy is highly effective but is associated with frequent unfavorable side effects. There is no fully published study yet exploring the safety, efficacy and required treatment duration of interferon-free treatment of acute hepatitis C virus monoinfection. Preliminary reports suggested that ledipasvir/sofosbuvir therapy is effective in acute hepatitis C but relapses were reported in HIV-coinfected patients after 6 weeks of treatment. Aims & Methods The German HepNet Acute HCV IV Study was designed as a single-arm, prospective multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir plus ledipasvir (SOF/LDV) for 6 weeks without ribavirin in patients with acute genotype 1 HCV monoinfection. We here report the final 24 weeks’ post-treatment results. Results Twenty patients were included by 10 centers (60% male, mean age 46 ± 12 years; 11 patients HCV genotype 1a, 9 patients genotype 1b). The main risk factors for HCV infection were sexual transmission (n = 11) and medical procedures/needle stick injuries (n = 5). Median alanine aminotransferase (ALT) and median bilirubin levels before start of antiviral treatment were 225 U/l (range 32–2716) and 13.6 µmol/l (range 5.13–111), respectively. ALT levels rapidly declined during therapy and values normalized already by treatment weeks 2 in nine patients and by week 4 in 17 patients. HCV RNA was undetectable by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test v2.0 by weeks 2, 4 and 6 in eight, 13, and 20 patients, respectively. SVR-12 was 100% and 19 patients have completed FU-week 24 and all remained HCV-RNA negative. One patient was lost to follow-up at week 24 post treatment. Conclusion Treatment for 6 weeks with LDV/SOF was well tolerated and highly effective in HCV genotype 1 monoinfected patients with acute hepatitis C. Virological response was durable after therapy for at least 24 weeks. A rapid improvement in biochemical disease activity was observed during therapy. Short-duration treatment of acute hepatitis C could prevent the spread of HCV in high-risk populations and may be cost-saving as compared with treatment of chronic hepatitis C. Disclosure of Interest Katja Deterding: Lecturer fees and travel grants from Gilead, MSD/Merck and AbbVie" @default.
• W3119376616 created "2021-01-18" @default.
• W3119376616 creator A5000083894 @default.
• W3119376616 creator A5000264792 @default.
• W3119376616 creator A5000369174 @default.
• W3119376616 creator A5000542169 @default.
• W3119376616 creator A5000542834 @default.
• W3119376616 creator A5000591965 @default.
• W3119376616 creator A5000839699 @default.
• W3119376616 creator A5001494473 @default.
• W3119376616 creator A5001994531 @default.
• W3119376616 creator A5002183557 @default.
• W3119376616 creator A5002457812 @default.
• W3119376616 creator A5002609664 @default.
• W3119376616 creator A5003018073 @default.
• W3119376616 creator A5003432782 @default.
• W3119376616 creator A5004336663 @default.
• W3119376616 creator A5004390210 @default.
• W3119376616 creator A5004670594 @default.
• W3119376616 creator A5006085908 @default.
• W3119376616 creator A5006572893 @default.
• W3119376616 creator A5007023316 @default.
• W3119376616 creator A5007803102 @default.
• W3119376616 creator A5007825130 @default.
• W3119376616 creator A5007861447 @default.
• W3119376616 creator A5008119575 @default.
• W3119376616 creator A5008123217 @default.
• W3119376616 creator A5008205761 @default.
• W3119376616 creator A5008586750 @default.
• W3119376616 creator A5009005245 @default.
• W3119376616 creator A5009113075 @default.
• W3119376616 creator A5010138676 @default.
• W3119376616 creator A5010254910 @default.
• W3119376616 creator A5010457446 @default.
• W3119376616 creator A5010886584 @default.
• W3119376616 creator A5011400814 @default.
• W3119376616 creator A5011957275 @default.
• W3119376616 creator A5012055170 @default.
• W3119376616 creator A5012143364 @default.
• W3119376616 creator A5012535821 @default.
• W3119376616 creator A5012669917 @default.
• W3119376616 creator A5013000285 @default.
• W3119376616 creator A5013428965 @default.
• W3119376616 creator A5013845819 @default.
• W3119376616 creator A5013900617 @default.
• W3119376616 creator A5014404501 @default.
• W3119376616 creator A5015470174 @default.
• W3119376616 creator A5015502391 @default.
• W3119376616 creator A5015911274 @default.
• W3119376616 creator A5016028088 @default.
• W3119376616 creator A5016355854 @default.
• W3119376616 creator A5016866834 @default.
• W3119376616 creator A5016948110 @default.
• W3119376616 creator A5017023759 @default.
• W3119376616 creator A5017140014 @default.
• W3119376616 creator A5017327952 @default.
• W3119376616 creator A5017967012 @default.
• W3119376616 creator A5018334166 @default.
• W3119376616 creator A5018413254 @default.
• W3119376616 creator A5018775239 @default.
• W3119376616 creator A5018899274 @default.
• W3119376616 creator A5019336200 @default.
• W3119376616 creator A5019470770 @default.
• W3119376616 creator A5020051678 @default.
• W3119376616 creator A5020766461 @default.
• W3119376616 creator A5020791158 @default.
• W3119376616 creator A5021033940 @default.
• W3119376616 creator A5021106928 @default.
• W3119376616 creator A5021665742 @default.
• W3119376616 creator A5022195195 @default.
• W3119376616 creator A5022284351 @default.
• W3119376616 creator A5023543240 @default.
• W3119376616 creator A5023716466 @default.
• W3119376616 creator A5024288783 @default.
• W3119376616 creator A5024442075 @default.
• W3119376616 creator A5024550661 @default.
• W3119376616 creator A5024581579 @default.
• W3119376616 creator A5024901363 @default.
• W3119376616 creator A5026015442 @default.
• W3119376616 creator A5026244899 @default.
• W3119376616 creator A5026399951 @default.
• W3119376616 creator A5026633857 @default.
• W3119376616 creator A5026697149 @default.
• W3119376616 creator A5026832798 @default.
• W3119376616 creator A5027111971 @default.
• W3119376616 creator A5027294559 @default.
• W3119376616 creator A5027381607 @default.
• W3119376616 creator A5027973321 @default.
• W3119376616 creator A5028309567 @default.
• W3119376616 creator A5028322606 @default.
• W3119376616 creator A5028514481 @default.
• W3119376616 creator A5029024517 @default.
• W3119376616 creator A5029066386 @default.
• W3119376616 creator A5029200390 @default.
• W3119376616 creator A5029428855 @default.
• W3119376616 creator A5029789134 @default.
• W3119376616 creator A5029994348 @default.
• W3119376616 creator A5030804963 @default.

• next